Jacobs Levy Equity Management’s C4 Therapeutics CCCC Stock Holding History

Jacobs Levy Equity Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Sell	25,111 -239,509	-91%	-$819K	﹤0.01%	920
2026 Q1	$696K	Buy	+264,620	New	+$623K	﹤0.01%	769
2025 Q4	–	Sell	-503,145	Closed	-$1.12M	–	940
2025 Q3	$1.12M	Buy	503,145 +61,410	+14%	+$147K	﹤0.01%	695
2025 Q2	$632K	Sell	441,735 -255,918	-37%	-$372K	﹤0.01%	840
2025 Q1	$1.12M	Buy	+697,653	New	+$2.08M	﹤0.01%	791
2024 Q1	–	Sell	-100,370	Closed	-$567K	–	948
2023 Q4	$567K	Sell	100,370 -764,111	-88%	-$1.74M	﹤0.01%	810
2023 Q3	$1.61M	Buy	864,481 +135,540	+19%	+$413K	0.01%	599
2023 Q2	$2M	Buy	728,941 +5,240	+0.7%	+$16.8K	0.01%	565
2023 Q1	$2.27M	Sell	723,701 -4,970	-0.7%	-$29.3K	0.01%	549
2022 Q4	$4.3M	Sell	728,671 -10,322	-1%	-$85.6K	0.03%	423
2022 Q3	$6.48M	Buy	738,993 +206,573	+39%	+$2.14M	0.05%	337
2022 Q2	$4.01M	Buy	+532,420	New	+$4.68M	0.03%	458
2021 Q3	–	Sell	-23,413	Closed	-$886K	–	1043
2021 Q2	$886K	Buy	+23,413	New	+$839K	0.01%	762

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management's CCCC Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its C4 Therapeutics (CCCC) stake by 91% in Q2 2026, selling an estimated $819K and leaving 25,111 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Jacobs Levy Equity Management first reported a position in CCCC in Q2 2021 and has held it in 13 quarters since. The position peaked at $6.48M in Q3 2022. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Jacobs Levy Equity Management held 25,111 shares of C4 Therapeutics worth $117K as of Q2 2026.
Jacobs Levy Equity Management sold 239,509 C4 Therapeutics shares in Q2 2026, an estimated $819K.
C4 Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #920 holding.
Jacobs Levy Equity Management first reported a position in C4 Therapeutics in Q2 2021 and has held it in 13 quarters since.
Jacobs Levy Equity Management's C4 Therapeutics position peaked at $6.48M in Q3 2022.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.